Crosstalk of Non-Apoptotic RCD Panel in Hepatocellular Carcinoma Reveals the Prognostic and Therapeutic Optimization

Shuo Li,Yaqi Xu,Xin Hu,Hao Chen,Xiaodan Xi,Fei Long,Yuan Rong,Jun Wang,Chunhui Yuan,Chen Liang,Fubing Wang
DOI: https://doi.org/10.1016/j.isci.2024.109901
IF: 5.8
2024-01-01
iScience
Abstract:Non-apoptotic regulated cell death (RCD) of tumor cells profoundly affects tumor progression and plays critical roles in determining response to immune checkpoint inhibitors (ICIs). Prognosis-distinctive HCC subtypes were identified by consensus cluster analysis based on the expressions of 507 non-apoptotic RCD genes obtained from databases and literature. Meanwhile, a set of bioinformatic tools was integrated to analyze the differences of the tumor immune microenvironment infiltration, genetic mutation, copy number variation, and epigenetics alternations within two subtypes. Finally, a non-apoptotic RCDRS signature was constructed and its reliability was evaluated in HCC patients' tissues. The high-RCDRS HCC subgroup showed a significantly lower overall survival and less sensitivity to ICIs compared to low-RCDRS subgroup, but higher sensitivity to cisplatin, paclitaxel, and sorafenib. Overall, we established an RCDRS panel consisting of four non-apoptotic RCD genes, which might be a promising predictor for evaluating HCC prognosis, guiding therapeutic decision-making, and ultimately improving patient outcomes.
What problem does this paper attempt to address?